Patients on REBLOZYL should be closely monitored for thromboembolic events, hypertension, extramedullary hematopoiesis (EMH), and potential fetal harm.

Precautions and Warnings for REBLOZYL

REBLOZYL carries several precautions that should be considered during treatment. It increases the risk of thromboembolism, particularly in patients with beta thalassemia, requiring vigilant monitoring for signs of clotting. Hypertension may also develop, and blood pressure should be checked regularly; anti-hypertensive treatment may be necessary. Additionally, there is a risk of extramedullary hematopoiesis (EMH), which can lead to serious complications, especially in beta thalassemia patients. Female patients of reproductive potential should be advised about the potential for embryo-fetal toxicity, and contraception should be used. For all patients, treatment should be discontinued if serious complications arise.